Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 1 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; macrogol 6000; sodium acid citrate; sodium dihydrogen citrate; sodium bicarbonate; sucralose; povidone; docusate sodium - jorveza is indicated for the treatment of eosinophilic esophagitis (eoe) in adults

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - daptomycin, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide - daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).,consideration should be given to official guidance on the appropriate use of antibacterial agents.,daptomycin is not indicated for the treatment of pneumonia.,adult patients (?18 years of age) complicated skin and skin structure infections,daptomycin is indicated for the treatment of adults (? 18 years of age) with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,staphylococcus aureus bloodstream infections (bacteraemia),daptomycin is indicated in adults (?18 years of age) for staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (rie), caused by methicillin-susceptible and methicillin-resistant isolates.,the efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to staphylococcus aureus has not been demonstrated. in the setting of staphylococcus aureus bacteraemia (sab), if a focus of infection is diagnosed as left-sided endocarditis after daptomycin therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy (see section 4.4 special warnings and precautions for use).,paediatric patients (1 to 17 years of age),daptomycin is not indicated for treatment of patients less than 1 year of age (see section 4.4 special warnings and precautions for use, paediatric use).,daptomycin has not been studied in treatment of infective endocarditis in children (see section 5.1 pharmacodynamic properties, clinical trials and section 4.4 special warnings and precautions for use).,complicated skin and skin structure infections,daptomycin is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,staphylococcus aureus bloodstream infections (bacteraemia),daptomycin is indicated in paediatric patients (1 to 17 years of age) with staphylococcus aureus bacteraemia not due to pneumonia, caused by daptomycin-susceptible isolates. empiric treatment should be reviewed based on the results of susceptibility testing. prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of staphylococcus aureus bacteraemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - daptomycin, quantity: 350 mg - injection, powder for - excipient ingredients: sodium hydroxide - daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).,consideration should be given to official guidance on the appropriate use of antibacterial agents.,daptomycin is not indicated for the treatment of pneumonia.,adult patients (?18 years of age) complicated skin and skin structure infections,daptomycin is indicated for the treatment of adults (? 18 years of age) with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,staphylococcus aureus bloodstream infections (bacteraemia),daptomycin is indicated in adults (?18 years of age) for staphylococcus aureus bloodstream infections (bacteraemia), including right-sided native valve infective endocarditis (rie), caused by methicillin-susceptible and methicillin-resistant isolates.,the efficacy of daptomycin in patients with prosthetic heart valves or in left-sided endocarditis due to staphylococcus aureus has not been demonstrated. in the setting of staphylococcus aureus bacteraemia (sab), if a focus of infection is diagnosed as left-sided endocarditis after daptomycin therapy has been initiated, then consideration should be given to instituting alternative antibacterial therapy (see section 4.4 special warnings and precautions for use).,paediatric patients (1 to 17 years of age),daptomycin is not indicated for treatment of patients less than 1 year of age (see section 4.4 special warnings and precautions for use, paediatric use).,daptomycin has not been studied in treatment of infective endocarditis in children (see section 5.1 pharmacodynamic properties, clinical trials and section 4.4 special warnings and precautions for use).,complicated skin and skin structure infections,daptomycin is indicated for the treatment of patients aged 1 to 17 years with complicated skin and skin structure infections (csssi) who require parenteral therapy and who have intolerance to alternative agents (especially penicillin allergy) or who have failed on other therapy, and when caused by organisms known to be susceptible to daptomycin.,staphylococcus aureus bloodstream infections (bacteraemia),daptomycin is indicated in paediatric patients (1 to 17 years of age) with staphylococcus aureus bacteraemia not due to pneumonia, caused by daptomycin-susceptible isolates. empiric treatment should be reviewed based on the results of susceptibility testing. prescribing should be in accordance with nationally or locally-endorsed guidelines for the treatment of staphylococcus aureus bacteraemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - solifenacin succinate, quantity: 10 mg (equivalent: solifenacin, qty 7.5 mg) - tablet, film coated - excipient ingredients: titanium dioxide; lactose monohydrate; triacetin; hypromellose; purified talc; magnesium stearate; iron oxide red - solifenacin dr.reddy's is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - solifenacin succinate, quantity: 5 mg (equivalent: solifenacin, qty 3.75 mg) - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; iron oxide yellow; hypromellose; triacetin; titanium dioxide; lactose monohydrate - solifenacin dr.reddy's is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 0.5 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; mannitol; macrogol 6000; sodium acid citrate; sodium dihydrogen citrate; sodium bicarbonate; sucralose; povidone; docusate sodium - jorveza? is indicated for the treatment of eosinophilic oesophagitis (eoe) in adults.

United States - English - NLM (National Library of Medicine)

dr. althea - dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - dr. althea premium intensive essence mask is a fast absorbing moisturizer that instantly hydrates the skin and improves the overall radiance. it restores elasticity and suppleness and gives a stunning glow on the face. [how to use] after prepping cleansed face with a toner, apply an appropriate amount of essence mask on the face and gently massage it until it is fully absorbed into the skin. considering the skin restoring cycle and for full benefits, use 3~4 pouches a week for four consecutive weeks.

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - capsules - budesonide 3 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileum (twisted intestine) and/or ascending colon (part of large bowel). collagenous colitis.autoimmune hepatitis.

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - granules gastro-resistant - budesonide 9 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileium (twisted intestine) and/or ascending colon (part of large bowel).collagenous colitis.

Israel - English - Ministry of Health

rafa laboratories ltd - budesonide - granules gastro-resistant - budesonide 9 mg - budesonide - acute mild to moderate crohn’s disease with involvement of the ileium (twisted intestine) and/or ascending colon (part of large bowel).collagenous colitis.